Hyperandrogenic oligomenorrhea and metabolic risks across menopausal transition

Alex J. Polotsky, Amanda A. Allshouse, Sybil L. Crawford, Sioban D. Harlow, Naila Khalil, Rasa Kazlauskaite, Nanette Santoro, Richard Legro

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Context: Although there is evidence of metabolic risks in young women with irregular menses and androgen excess, persistence of risks after menopause is unclear. Objective: The objective of the study was to determine the impact of menopause on the cardiometabolic profile in women with high androgens and a history of menstrual irregularity. Methods: Study of Women's Health Across the Nation is a longitudinal cohort study. Data from 1929womenwithout metabolic syndrome (MetS) at baseline were analyzed for incidence of MetS, self-reported stroke, and myocardial infarction. Cox hazard ratios (HRs) were estimated, adjusting for age, ethnicity, body mass, smoking, menopausal status, and study site. Results: Among MetS-free women at baseline, 497 new cases were identified during 20 249 woman- years of follow-up over 12 years. Women with hyperandrogenemia (HA) and oligomenorrhea (Oligo) developed incident cases of MetS at a comparable rate compared with their counterparts: eumenorrheic, normoandrogenic women [HR 1.4 (0.9 -2.2)], oligomenorrheic, normoandrogenic women [HR 1.3 (0.8 -2.2)], and eumenorrheic hyperandrogenic women [HR 1.2 (0.7-1.8)]. Smoking and obesity were the strongest predictors of incident MetS. There was no significant difference in incidence of self-reported stroke or MI by HA/Oligo status. Conclusions: Longitudinal evidence suggests that a history of androgen excess and menstrual irregularity is not associated with worsening of metabolic health after menopause. Our findings challenge the notion that a history of concurrent HA and Oligo reflects ongoing cardiometabolic risk in postmenopausal women.

Original languageEnglish (US)
Pages (from-to)2120-2127
Number of pages8
JournalJournal of Clinical Endocrinology and Metabolism
Volume99
Issue number6
DOIs
StatePublished - Jan 1 2014

Fingerprint

Oligomenorrhea
Hazards
Androgens
Menopause
Health
Smoking
Stroke
Menstruation
Incidence
Women's Health
Longitudinal Studies
Cohort Studies
Obesity
Myocardial Infarction

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • Clinical Biochemistry
  • Endocrinology
  • Biochemistry, medical
  • Endocrinology, Diabetes and Metabolism

Cite this

Polotsky, A. J., Allshouse, A. A., Crawford, S. L., Harlow, S. D., Khalil, N., Kazlauskaite, R., ... Legro, R. (2014). Hyperandrogenic oligomenorrhea and metabolic risks across menopausal transition. Journal of Clinical Endocrinology and Metabolism, 99(6), 2120-2127. https://doi.org/10.1210/jc.2013-4170
Polotsky, Alex J. ; Allshouse, Amanda A. ; Crawford, Sybil L. ; Harlow, Sioban D. ; Khalil, Naila ; Kazlauskaite, Rasa ; Santoro, Nanette ; Legro, Richard. / Hyperandrogenic oligomenorrhea and metabolic risks across menopausal transition. In: Journal of Clinical Endocrinology and Metabolism. 2014 ; Vol. 99, No. 6. pp. 2120-2127.
@article{3ba5aa882c18482eaa6d489c3f39c55f,
title = "Hyperandrogenic oligomenorrhea and metabolic risks across menopausal transition",
abstract = "Context: Although there is evidence of metabolic risks in young women with irregular menses and androgen excess, persistence of risks after menopause is unclear. Objective: The objective of the study was to determine the impact of menopause on the cardiometabolic profile in women with high androgens and a history of menstrual irregularity. Methods: Study of Women's Health Across the Nation is a longitudinal cohort study. Data from 1929womenwithout metabolic syndrome (MetS) at baseline were analyzed for incidence of MetS, self-reported stroke, and myocardial infarction. Cox hazard ratios (HRs) were estimated, adjusting for age, ethnicity, body mass, smoking, menopausal status, and study site. Results: Among MetS-free women at baseline, 497 new cases were identified during 20 249 woman- years of follow-up over 12 years. Women with hyperandrogenemia (HA) and oligomenorrhea (Oligo) developed incident cases of MetS at a comparable rate compared with their counterparts: eumenorrheic, normoandrogenic women [HR 1.4 (0.9 -2.2)], oligomenorrheic, normoandrogenic women [HR 1.3 (0.8 -2.2)], and eumenorrheic hyperandrogenic women [HR 1.2 (0.7-1.8)]. Smoking and obesity were the strongest predictors of incident MetS. There was no significant difference in incidence of self-reported stroke or MI by HA/Oligo status. Conclusions: Longitudinal evidence suggests that a history of androgen excess and menstrual irregularity is not associated with worsening of metabolic health after menopause. Our findings challenge the notion that a history of concurrent HA and Oligo reflects ongoing cardiometabolic risk in postmenopausal women.",
author = "Polotsky, {Alex J.} and Allshouse, {Amanda A.} and Crawford, {Sybil L.} and Harlow, {Sioban D.} and Naila Khalil and Rasa Kazlauskaite and Nanette Santoro and Richard Legro",
year = "2014",
month = "1",
day = "1",
doi = "10.1210/jc.2013-4170",
language = "English (US)",
volume = "99",
pages = "2120--2127",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "6",

}

Polotsky, AJ, Allshouse, AA, Crawford, SL, Harlow, SD, Khalil, N, Kazlauskaite, R, Santoro, N & Legro, R 2014, 'Hyperandrogenic oligomenorrhea and metabolic risks across menopausal transition', Journal of Clinical Endocrinology and Metabolism, vol. 99, no. 6, pp. 2120-2127. https://doi.org/10.1210/jc.2013-4170

Hyperandrogenic oligomenorrhea and metabolic risks across menopausal transition. / Polotsky, Alex J.; Allshouse, Amanda A.; Crawford, Sybil L.; Harlow, Sioban D.; Khalil, Naila; Kazlauskaite, Rasa; Santoro, Nanette; Legro, Richard.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 99, No. 6, 01.01.2014, p. 2120-2127.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Hyperandrogenic oligomenorrhea and metabolic risks across menopausal transition

AU - Polotsky, Alex J.

AU - Allshouse, Amanda A.

AU - Crawford, Sybil L.

AU - Harlow, Sioban D.

AU - Khalil, Naila

AU - Kazlauskaite, Rasa

AU - Santoro, Nanette

AU - Legro, Richard

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Context: Although there is evidence of metabolic risks in young women with irregular menses and androgen excess, persistence of risks after menopause is unclear. Objective: The objective of the study was to determine the impact of menopause on the cardiometabolic profile in women with high androgens and a history of menstrual irregularity. Methods: Study of Women's Health Across the Nation is a longitudinal cohort study. Data from 1929womenwithout metabolic syndrome (MetS) at baseline were analyzed for incidence of MetS, self-reported stroke, and myocardial infarction. Cox hazard ratios (HRs) were estimated, adjusting for age, ethnicity, body mass, smoking, menopausal status, and study site. Results: Among MetS-free women at baseline, 497 new cases were identified during 20 249 woman- years of follow-up over 12 years. Women with hyperandrogenemia (HA) and oligomenorrhea (Oligo) developed incident cases of MetS at a comparable rate compared with their counterparts: eumenorrheic, normoandrogenic women [HR 1.4 (0.9 -2.2)], oligomenorrheic, normoandrogenic women [HR 1.3 (0.8 -2.2)], and eumenorrheic hyperandrogenic women [HR 1.2 (0.7-1.8)]. Smoking and obesity were the strongest predictors of incident MetS. There was no significant difference in incidence of self-reported stroke or MI by HA/Oligo status. Conclusions: Longitudinal evidence suggests that a history of androgen excess and menstrual irregularity is not associated with worsening of metabolic health after menopause. Our findings challenge the notion that a history of concurrent HA and Oligo reflects ongoing cardiometabolic risk in postmenopausal women.

AB - Context: Although there is evidence of metabolic risks in young women with irregular menses and androgen excess, persistence of risks after menopause is unclear. Objective: The objective of the study was to determine the impact of menopause on the cardiometabolic profile in women with high androgens and a history of menstrual irregularity. Methods: Study of Women's Health Across the Nation is a longitudinal cohort study. Data from 1929womenwithout metabolic syndrome (MetS) at baseline were analyzed for incidence of MetS, self-reported stroke, and myocardial infarction. Cox hazard ratios (HRs) were estimated, adjusting for age, ethnicity, body mass, smoking, menopausal status, and study site. Results: Among MetS-free women at baseline, 497 new cases were identified during 20 249 woman- years of follow-up over 12 years. Women with hyperandrogenemia (HA) and oligomenorrhea (Oligo) developed incident cases of MetS at a comparable rate compared with their counterparts: eumenorrheic, normoandrogenic women [HR 1.4 (0.9 -2.2)], oligomenorrheic, normoandrogenic women [HR 1.3 (0.8 -2.2)], and eumenorrheic hyperandrogenic women [HR 1.2 (0.7-1.8)]. Smoking and obesity were the strongest predictors of incident MetS. There was no significant difference in incidence of self-reported stroke or MI by HA/Oligo status. Conclusions: Longitudinal evidence suggests that a history of androgen excess and menstrual irregularity is not associated with worsening of metabolic health after menopause. Our findings challenge the notion that a history of concurrent HA and Oligo reflects ongoing cardiometabolic risk in postmenopausal women.

UR - http://www.scopus.com/inward/record.url?scp=84902355221&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902355221&partnerID=8YFLogxK

U2 - 10.1210/jc.2013-4170

DO - 10.1210/jc.2013-4170

M3 - Article

C2 - 24517154

AN - SCOPUS:84902355221

VL - 99

SP - 2120

EP - 2127

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 6

ER -

Polotsky AJ, Allshouse AA, Crawford SL, Harlow SD, Khalil N, Kazlauskaite R et al. Hyperandrogenic oligomenorrhea and metabolic risks across menopausal transition. Journal of Clinical Endocrinology and Metabolism. 2014 Jan 1;99(6):2120-2127. https://doi.org/10.1210/jc.2013-4170